On Friday 15 September, the European Commission authorised the Covid-19 vaccine adapted with Spikevax XBB.1.5, developed by Moderna. This is the third adaptation of this vaccine to respond to new variants of Covid-19 (see EUROPE B13241A13).
The European Medicines Agency (EMA) has carried out a rigorous evaluation of the vaccine under the accelerated assessment mechanism. The Commission has authorised this vaccine under a fast-track procedure so that Member States can prepare in time for...